Search

Your search keyword '"Markulev, Connie"' showing total 197 results

Search Constraints

Start Over You searched for: Author "Markulev, Connie" Remove constraint Author: "Markulev, Connie"
197 results on '"Markulev, Connie"'

Search Results

1. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study.

2. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis

3. Machine learning based prediction and the influence of complement – Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial

4. The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial

5. The association between migrant status and transition in an ultra-high risk for psychosis population

6. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

7. Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

9. Urgent call for research into imagery rescripting to reduce suicidal mental imagery: clinical research considerations.

10. Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

11. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

12. Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial

14. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

15. Clinical trajectories in the ultra-high risk for psychosis population

18. Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis

21. Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial

22. NEURAPRO‐E study protocol: a multicentre randomized controlled trial of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders

23. Machine learning based prediction and the influence of complement - coagulation pathway proteins on clinical outcome: results from the NEURAPRO trial

24. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial

25. Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis

27. Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing

29. Author response: Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing

31. Greater preference for eveningness is associated with negative symptoms in an ultra‐high risk for psychosis sample

32. Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial (Frontiers in Psychiatry, (2019), 10, 10.3389/fpsyt.2019.00393)

33. Omega‐3 fatty acids and neurocognitive ability in young people at ultra‐high risk for psychosis

34. Distress Related to Attenuated Psychotic Symptoms: Static and Dynamic Association With Transition to Psychosis, Nonremission, and Transdiagnostic Symptomatology in Clinical High-Risk Patients in an International Intervention Trial.

35. Prediction of clinical outcomes beyond psychosis in the ultra‐high risk for psychosis population

36. Characterization and Prediction of Clinical Pathways of Vulnerability to Psychosis through Graph Signal Processing

37. T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL

38. Improving Mood with Physical ACTivity (IMPACT) trial: a cluster randomised controlled trial to determine the effectiveness of a brief physical activity behaviour change intervention on depressive symptoms in young people, compared with psychoeducation, in addition to routine clinical care within youth mental health services—a protocol study

39. Omega‐3 fatty acids and neurocognitive ability in young people at ultra‐high risk for psychosis.

42. Prediction of clinical outcomes beyond psychosis in the ultra‐high risk for psychosis population.

43. The association between migrant status and transition in an ultra-high risk for psychosis population.

44. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

45. The relationship between childhood trauma and clinical characteristics in ultra-high risk for psychosis youth

46. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youth at Ultra-High Risk for Psychosis

47. Stability of retrospective self‐reports of childhood trauma in first‐episode psychosis.

49. F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS

50. O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL

Catalog

Books, media, physical & digital resources